The Cooper Cos., Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2166485019
USD
77.03
1.19 (1.57%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About The Cooper Cos., Inc. stock-summary
stock-summary
The Cooper Cos., Inc.
Pharmaceuticals & Biotechnology
The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses. CooperVision services three primary regions: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific. CooperVision offers spherical, aspherical, toric, multifocal and toric multifocal lens products in various modalities. CooperVision's products are primarily manufactured at its facilities located in the United Kingdom, Puerto Rico, Hungary, Costa Rica and New York. CooperSurgical offers an array of products and services focused on advancing the health of families through a portfolio of products and services focusing on women's health, fertility and diagnostics.
Company Coordinates stock-summary
Company Details
6101 Bollinger Canyon Rd Ste 500 , SAN RAMON CA : 94583-5177
stock-summary
Tel: 1 925 46036001 925 4603663
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 132 Schemes (45.86%)

Foreign Institutions

Held by 353 Foreign Institutions (27.24%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. A. Thomas Bender
Independent Chairman of the Board
Mr. Albert White
President, Chief Executive Officer, Director
Dr. Allan Rubenstein
Independent Vice Chairman of the Board, Lead Director
Mr. Robert Weiss
Director
Ms. Colleen Jay
Independent Director
Mr. William Kozy
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,060 Million
(Quarterly Results - Jul 2025)
Net Profit:
98 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 13,979 Million (Small Cap)

stock-summary
P/E

36.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.28

stock-summary
Return on Equity

4.88%

stock-summary
Price to Book

1.67